Ovation的动态

If you are attending the American College of Rheumatology #ACRConvergence conference next week, stop by our booth to learn about some important new advancements in the diagnosis of #axSpA and visit our poster to engage with our scientific team. We'll be unveiling some exciting announcements in the week leading up to the conference! #Diagnostics #RheumatoidArthritis #AxialSpondyloarthritis #RA #ACR24

In this episode of “Answers From the Lab,” Bill Morice, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, Inc., is enhancing the care and quality of life for patients affected by systemic lupus erythematosus. https://bit.ly/4e9aXt0

The World CB & CDx Summit in Boston is off to a great start! Swing by Booth 22 to visit our team and say hello! ?? And be sure to catch Azad Gucwa, Ph.D., MT(ASCP) tomorrow at 2:20p ET, she'll be presenting on: ? Leveraging single-cell multi-modal analysis to get a more comprehensive view of multiple myeloma disease progression, therapy response and resistance, and therapy safety & efficacy ? Integrating SNVs, zygosity, CNVs, VDJ clonotype, and surface immunophenotype at the single-cell level, while measuring the transduction efficiency and vector copy number of potential CAR-T therapies ? Assessing genome integrity through genome-wide CNV analysis at the single-cell level and leverage cohort-level analysis to guide therapeutic and clinical development

Quite the journey to get this paper out! “Rare SH2B3 coding variants in lupus patients impair B cell tolerance and predispose to autoimmunity” our new paper highlighting the previously unappreciated role for SH2B3 in human B cell tolerance and lupus risk. Read it here: https://lnkd.in/en3M4KGu

?? Continuing Our Video Series: RRI Symposium - Stockholm 2024! ??? ? We are excited to share the next session from the Renal Research Institute's Symposium in Stockholm. This week's feature highlights Dr. Natalie Staplin, Associate Professor and Senior Statistician at the University of Oxford, presenting on "SGLT2i in Different Patient Groups: Effect on CKD Progression.”? ? ?? Session Spotlight: SGLT2iin Different Patient Groups? Dr. Staplin discusses the recent findings from the EMPA-KIDNEY trial, focusing on the impact of SGLT2 inhibitors on the progression of chronic kidney disease (CKD) across various patient subgroups. Key topics include the effects on kidney function decline, the importance of considering different patient characteristics, and the broader implications for CKD management.? ? ?? Watch Now on our YouTube Channel: https://lnkd.in/eM9_AMx8?

It's May 22 and we're making NF2-SWN and SWN visible! Thanks to recent advancements, we know NF, while still a rare disease, is indeed more common than we thought. In fact, some type of schwannomatosis (including NF2-related schwannomatosis) occurs in approximately 1 in 20,000 births! Join us this afternoon at 2PM ET for a virtual meeting with Vanessa Merker, PhD, and Frank Buono, PhD, who will present their most recent project: to develop a new patient-reported measure of quality of life in people with NF2-related schwannomatosis that can capture the full range of symptoms that matter to patients. Their goal is to improve how we measure NF patients' quality of life within clinical trials, leading to the development and approval of new treatments that not only impact tumor size but also improve NF2-SWN patients' day-to-day quality of life. Live captions will be available. ctf.org/may22

Only a few weeks to go! ?? Join us on October 31 for an insightful session with Matterworks on "A Scalable Approach to Absolute Quantitation in Metabolomics". ?? In this webinar we will explore the importance of metabolomics in disease research, and the challenges associated with LC-MS based #metabolomics studies. Don't miss out on this opportunity! Register before it's too late: https://ow.ly/6FTA50Tunh5

Just 1 week to go! ?? Join us on October 31 for an insightful session with Matterworks on "A Scalable Approach to Absolute Quantitation in Metabolomics". ?? In this webinar we will explore the importance of metabolomics in disease research, and the challenges associated with LC-MS based #metabolomics studies. Don't miss out on this opportunity! Register before it's too late: https://ow.ly/6FTA50Tunh5

Upcoming webinar on mini-organs - for the organoid-curious!

Take a look at the re-vamped fibrosis page on PhenoVista's website here! https://hubs.ly/Q02sYTf20 There's a general overview of our capabilities in this disease area and a case study of a completed client project. If you don't find what you're looking for or want to discuss challenges you're facing in fibrosis R&D, shoot let's chat!